JPH06100595B2 - Liquid separating agent - Google Patents
Liquid separating agentInfo
- Publication number
- JPH06100595B2 JPH06100595B2 JP61039736A JP3973686A JPH06100595B2 JP H06100595 B2 JPH06100595 B2 JP H06100595B2 JP 61039736 A JP61039736 A JP 61039736A JP 3973686 A JP3973686 A JP 3973686A JP H06100595 B2 JPH06100595 B2 JP H06100595B2
- Authority
- JP
- Japan
- Prior art keywords
- liquid separating
- separating agent
- agent
- forming material
- separation layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000007788 liquid Substances 0.000 title claims description 34
- 239000003795 chemical substances by application Substances 0.000 claims description 30
- 238000000926 separation method Methods 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 14
- 239000003349 gelling agent Substances 0.000 claims description 9
- 230000005484 gravity Effects 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000004711 α-olefin Substances 0.000 claims description 5
- -1 β-unsaturated dicarboxylic acid diester Chemical class 0.000 claims description 5
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims description 4
- 229920001083 polybutene Polymers 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003921 oil Substances 0.000 description 8
- 238000005192 partition Methods 0.000 description 6
- 239000013008 thixotropic agent Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000009974 thixotropic effect Effects 0.000 description 3
- FMZUHGYZWYNSOA-VVBFYGJXSA-N (1r)-1-[(4r,4ar,8as)-2,6-diphenyl-4,4a,8,8a-tetrahydro-[1,3]dioxino[5,4-d][1,3]dioxin-4-yl]ethane-1,2-diol Chemical compound C([C@@H]1OC(O[C@@H]([C@@H]1O1)[C@H](O)CO)C=2C=CC=CC=2)OC1C1=CC=CC=C1 FMZUHGYZWYNSOA-VVBFYGJXSA-N 0.000 description 2
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 229940087101 dibenzylidene sorbitol Drugs 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 229940114072 12-hydroxystearic acid Drugs 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001612 separation test Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910021647 smectite Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Sampling And Sample Adjustment (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Description
【発明の詳細な説明】 〔産業上の利用分野〕 本発明は液体分離剤に関する。詳しくは、液体中に共存
する特定の成分と他の成分とをその比重差を利用し分離
する際、両成分の中間の比重を有し、両成分の間に隔壁
を形成することによつて両成分の分離操作を容易にする
目的に使用される液体分離剤に関する。TECHNICAL FIELD The present invention relates to a liquid separating agent. Specifically, when a specific component coexisting in a liquid and another component are separated by utilizing the difference in specific gravities, they have an intermediate specific gravity of both components and form a partition wall between both components. The present invention relates to a liquid separating agent used for facilitating the separation operation of both components.
従来、この主の液体分離剤としては、シリコーン油、塩
素化ポリブテン油或いはα−オレフインとマレイン酸ジ
エステルとの共重合物などの高粘度の油を分離層形成材
料に用い、これに疏水性微粉末シリカや疏水性スメクタ
イト粘土などの無機微粉末をチクソトロピー化剤として
使用することによつて、チクソトロピー性を有するゲル
状物となし、遠心分離操作時には流動性を示すが、その
他の場合は非流動性状態を保つような液体分離剤が知ら
れている。Conventionally, as the main liquid separating agent, a highly viscous oil such as silicone oil, chlorinated polybutene oil, or a copolymer of α-olefin and maleic acid diester has been used as a material for forming a separation layer, which has a high hydrophobicity. By using an inorganic fine powder such as powdered silica or hydrophobic smectite clay as a thixotropic agent, a gel-like substance having thixotropic properties is obtained, which shows fluidity during centrifugation, but otherwise non-fluid Liquid separating agents that maintain the sexual state are known.
しかし、これら従来の液体分離剤は、いずれも分離層形
成材料に不溶性の無機微粉末をチクソトロピー化剤とし
て分散状態で使用していることから、本質的に不均一な
系であり、このため加熱処理や長期保存或いは遠心分離
操作などの条件下で、分離層形成材料とチクソトロピー
化剤との相分離が生じ、ゲルの物性変化による隔壁機能
の低下や油分の分離による分離成分への汚染などを起こ
すといつた欠点があつた。However, these conventional liquid separating agents are essentially inhomogeneous systems because they use inorganic fine powder insoluble in the separation layer forming material as a thixotropic agent in a dispersed state, and therefore, heating by heating Under conditions such as treatment, long-term storage or centrifugation operation, phase separation of the separation layer forming material and thixotropic agent occurs, deterioration of partition function due to physical property change of gel and contamination of separated components due to oil separation. When I wake it up
本発明の目的は、これらの欠点の無い、実用的に優れた
液体分離剤を提供することにある。An object of the present invention is to provide a practically excellent liquid separating agent that does not have these drawbacks.
本発明者らは、かかる目的を達成するために鋭意検討を
重ねた結果、本発明に到達した。The present inventors have arrived at the present invention as a result of intensive studies to achieve such an object.
即ち、本発明の要旨は、塩素化ポリブテン及びα−オレ
フィンとα，β−不飽和ジカルボン酸ジエステルとの共
重合体からなる群から選ばれた分離層形成材料と有機系
ゲル化剤とからなる組成物であることを特徴とする液体
分離剤、に存する。That is, the gist of the present invention consists of a separation layer forming material selected from the group consisting of chlorinated polybutene and a copolymer of α-olefin and α, β-unsaturated dicarboxylic acid diester, and an organic gelling agent. A liquid separating agent, which is a composition.
以下、本発明について詳細に説明する。Hereinafter, the present invention will be described in detail.
本発明の液体分離剤に用いる分離層形成材料は、塩素化
ポリブテン及びα−オレフィンとα，β−不飽和ジカル
ボン酸ジエステルとの共重合体からなる群から選ばれ、
その比重が分離されるべき液体中の二成分の中間領域に
あるものであれば、低粘度のものから高粘度の高分子油
状物まで使用することが出来る。実用上、安定で適度の
流動性及びゲル化性を与える点で、好ましくは温度25℃
での粘度が200〜60万cpsの範囲の高分子油状物が適して
いる。The separation layer forming material used for the liquid separating agent of the present invention is selected from the group consisting of chlorinated polybutene and a copolymer of α-olefin and α, β-unsaturated dicarboxylic acid diester,
As long as the specific gravity is in the intermediate region between the two components in the liquid to be separated, a low-viscosity polymer oil or a high-viscosity polymer oil can be used. In terms of practical use, a temperature of 25 ° C is preferable from the viewpoint of providing stable and appropriate fluidity and gelation property.
Polymer oils with a viscosity in the range of 200 to 600,000 cps are suitable.
本発明の液体分離剤に用いる有機系ゲル化剤としては、
例えばソルビトールとベンズアルデヒドとの縮合物であ
るジベンジリデンソルビトール、トリベンジリデンソル
ビトール或いはアルキル置換ジベンジリデンソルビトー
ルなどや水溶性蛋白のニトロフミン酸付加物、水添ヒマ
シ油、12−ヒドロキシステアリン酸などがあげられる。As the organic gelling agent used in the liquid separating agent of the present invention,
Examples thereof include dibenzylidene sorbitol which is a condensate of sorbitol and benzaldehyde, tribenzylidene sorbitol, alkyl-substituted dibenzylidene sorbitol, and the like, nitrohumic acid adducts of water-soluble proteins, hydrogenated castor oil, and 12-hydroxystearic acid.
分離層形成材料に対する有機系ゲル化剤の適当な添加量
は、分離層形成材料の極性の強さおよび粘度によつて異
なり、一般に極性が増す程また粘度が低い程、適当な添
加量は増加する傾向にあるが、通常は分離層形成材料10
0重量部に対して0.02〜５重量部、好ましくは0.1〜１重
量部の範囲である。The appropriate addition amount of the organic gelling agent to the separation layer forming material depends on the polarity strength and viscosity of the separation layer forming material. Generally, the more the polarity is increased and the lower the viscosity is, the more appropriate addition amount is increased. However, usually, the separation layer forming material 10
The amount is 0.02 to 5 parts by weight, preferably 0.1 to 1 part by weight, relative to 0 parts by weight.
有機系ゲル化剤の添加量が少な過ぎる場合は、液体の分
離操作の際、ゲルの強度が不十分のために隔壁が流動し
てしまい、十分に機能しない。If the amount of the organic gelling agent added is too small, the partition wall will flow due to insufficient gel strength during the liquid separation operation, and the partition wall will not function sufficiently.
また該添加量が多過ぎる場合は、逆に流動性が不十分と
なるために隔壁形成のための移行性が不足してしまい十
分に機能しない。On the other hand, if the amount of addition is too large, the fluidity becomes insufficient, and the transferability for forming the partition wall becomes insufficient, which does not function sufficiently.
本発明の液体分離剤を構成する組成物の好適な物性は、
分離処理に供される液体の種類にも依存するが、例えば
これを血清または血漿の分離剤として使用する場合は、
温度25℃における比重が血球との中間、即ち1.035〜1.0
60であり、また粘度が20万〜200万cpsの範囲であるのが
適当である。Suitable physical properties of the composition constituting the liquid separating agent of the present invention,
Depending on the type of liquid used for the separation treatment, for example, when it is used as a serum or plasma separating agent,
The specific gravity at a temperature of 25 ° C is between that of blood cells, that is, 1.035 to 1.0
A value of 60 and a viscosity in the range of 200,000 to 2,000,000 cps are suitable.
本発明の液体分離剤の製造方法としては、分離層形成材
料を温度100〜200℃程度の範囲に加熱し、これに有機系
ゲル化剤を所定量添加し、均一に溶解するまで１〜５時
間程度加熱撹拌することによつて容易に製造される。な
お、血清分離剤として利用する場合は、熱時に上記液体
分離剤を採血管に分注し、冷却ゲル化させることにより
極めて容易に使用することが出来る。As the method for producing the liquid separating agent of the present invention, the separation layer forming material is heated to a temperature range of about 100 to 200 ° C., and a predetermined amount of the organic gelling agent is added to the separating layer forming material until it is uniformly dissolved. It can be easily produced by heating and stirring for about an hour. When used as a serum separating agent, it can be used very easily by dispensing the above liquid separating agent into a blood collection tube when heated and gelling by cooling.
次に本発明を実施例によりさらに具体的に説明するが、
本発明は、その要旨を超えない限り以下の実施例によつ
て限定されるものではない。Next, the present invention will be described more specifically with reference to Examples.
The present invention is not limited to the following examples unless it exceeds the gist.
実施例１（液体分離剤の製造） 表１に示す組成で、分離層形成材料と有機系ゲル化剤と
を４つ口フラスコに仕込み、190℃に加熱し、２時間撹
拌して、有機系ゲル化剤を溶解し、冷却すると、チクソ
トロピー性を有し、ゲル状の液体分離剤が得られた。性
状を表１に併せて示す。Example 1 (Production of Liquid Separating Agent) With the composition shown in Table 1, a separation layer forming material and an organic gelling agent were placed in a four-necked flask, heated to 190 ° C. and stirred for 2 hours to prepare an organic system. When the gelling agent was dissolved and cooled, a gel-like liquid separating agent having a thixotropic property was obtained. Properties are also shown in Table 1.
実施例２（評価−血清分離テスト） 実施例１で製造した各液体分離剤2ccと採血した全血試
料とを各スピツツ管に入れ、放置した。 Example 2 (Evaluation-Serum Separation Test) 2 cc of each liquid separating agent prepared in Example 1 and a sample of the collected whole blood were placed in each Spitz tube and allowed to stand.
血液凝固が進行し、血清と血餅とに分離したのち、3,00
0rpmで10分間遠心分離したところ、いずれの液体分離剤
についても、血清と血餅との中間に液体分離剤のゲルが
形成された。血清は、デカンテーシヨンにより容易にス
ピツツ管から取り出すことができた。After blood coagulation progressed and separated into serum and blood clot, 3,000
When centrifuged at 0 rpm for 10 minutes, a gel of the liquid separating agent was formed between the serum and the blood clot for any of the liquid separating agents. Serum could be easily removed from the Spitz tube by decantation.
実施例３（評価−安定性） シリコーンオイル（比重▲ｄ25 4▼0.992、粘度100cPs
（25℃））100重量部と疎水性シリカ微粉末（アエロジ
ルＲ−972、日本アエロジル社製）３重量部とを三本ロ
ールにて十分に混練し、チクソトロピー性のあるゲルを
調製した。このゲルと実施例１で製造した液体分離剤と
を各2ccずつ各スピツツ管に入れ、40℃で１週間保存し
て、ゲルの安定性を見た。Example 3 (Evaluation-Stability) Silicone oil (specific gravity ▲ d 25 4 ▼ 0.992, viscosity 100 cPs
(25 ° C.)) 100 parts by weight and 3 parts by weight of hydrophobic silica fine powder (Aerosil R-972, manufactured by Nippon Aerosil Co., Ltd.) were sufficiently kneaded with a three-roll to prepare a thixotropic gel. This gel and the liquid separating agent prepared in Example 1 were put into each Spitz tube by 2 cc and stored at 40 ° C. for 1 week, and the stability of the gel was examined.
結果を表２に示す。The results are shown in Table 2.
安定性の評価基準 ○：分離なし △：油分の分離あり ×：相分離 〔発明の効果〕 本発明の液体分離剤は、無色透明で完全に均一な系を形
成しており、従来の無機微粉末など不溶性チクソトロピ
ー化剤で処理した液体分離剤が、いずれも不透明で不均
一な系であるのに対して、全くその性状を異にしてお
り、実用上、極めて有用な特性を有している。Stability evaluation criteria ○: No separation △: Oil content separation ×: Phase separation (Effect of the invention) The liquid separating agent of the present invention forms a colorless and transparent and completely uniform system, and liquid separating agents treated with an insoluble thixotropic agent such as conventional inorganic fine powder are opaque and non-transparent. Although it is a homogeneous system, it has completely different properties and has extremely useful properties in practical use.
即ち、本発明の液体分離剤は、均一な系を形成している
ので、加熱処理や長期保存あるいは遠心分離操作などの
条件下での、分離層形成材料とチクソトロピー化剤との
相分離現象の心配がなく、隔壁としての機能低下や油分
分離による汚染などを起さない。また、製造面において
も、不溶性微粉末状チクソトロピー化剤を使用する従来
の液体分離剤が、三本ロールや混練機などによる非能率
な分散・混練工程を必要とするのに対し、単なる加熱溶
解のみで製造出来ることから極めて製造コストが安価と
なる。さらにまた、使用済みの液体分離剤の処理に際し
て、灰分発生によるトラブルが全くなく、極めて容易に
焼却処理が出来る。That is, since the liquid separating agent of the present invention forms a uniform system, under conditions such as heat treatment, long-term storage or centrifugation operation, the phase separation phenomenon of the separation layer forming material and the thixotropic agent There is no need to worry, and it will not cause deterioration of the function as a partition or contamination due to oil separation. Further, in terms of manufacturing, the conventional liquid separating agent using an insoluble fine powder thixotropic agent requires an inefficient dispersion / kneading process using a three-roll or kneader, whereas it is simply heated and melted. Since it can be manufactured only by itself, the manufacturing cost is extremely low. Furthermore, when treating the used liquid separating agent, there is no trouble due to the generation of ash, and the incineration treatment can be performed very easily.
Claims (5)
α，β−不飽和ジカルボン酸ジエステルとの共重合体か
らなる群から選ばれた分離層形成材料と有機系ゲル化剤
とからなる組成物であることを特徴とする液体分離剤。1. A composition comprising a separation layer-forming material selected from the group consisting of copolymers of chlorinated polybutene and α-olefin and α, β-unsaturated dicarboxylic acid diester, and an organic gelling agent. A liquid separating agent characterized by being.
において、分離層形成材料が、α−オレフィンとα，β
−不飽和ジカルボン酸ジエステルとの共重合体からなる
ものであることを特徴とするもの。2. The liquid separating agent according to claim 1, wherein the separation layer forming material is α-olefin and α, β.
-A compound characterized by comprising a copolymer with an unsaturated dicarboxylic acid diester.
液体分離剤において、有機系ゲル化剤がソルビトールと
ベンズアルデヒドとの縮合物であることを特徴とするも
の。3. The liquid separating agent according to claim 1 or 2, wherein the organic gelling agent is a condensate of sorbitol and benzaldehyde.
に記載の液体分離剤において、分離される液体が血清ま
たは血漿であることを特徴とするもの。4. The liquid separating agent according to any one of claims 1 to 3, wherein the liquid to be separated is serum or plasma.
において、該組成物の温度25℃における比重が1.035〜
1.060であり、粘度が20万〜200万cpsであることを特徴
とするもの。5. The liquid separating agent according to claim 4, wherein the composition has a specific gravity of 1.035 to 25 ° C.
It has a viscosity of 1.060 and a viscosity of 200,000 to 2,000,000 cps.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61039736A JPH06100595B2 (en) | 1986-02-25 | 1986-02-25 | Liquid separating agent |
| US07/013,340 US4828720A (en) | 1986-02-25 | 1987-02-11 | Liquid separating agent and liquid separating method |
| DE19873704854 DE3704854A1 (en) | 1986-02-25 | 1987-02-16 | LIQUID SEPARATORS AND METHOD FOR SEPARATING LIQUIDS |
| GB8703896A GB2188642B (en) | 1986-02-25 | 1987-02-19 | Agent for and method of separating components of a liquid |
| FR8702380A FR2598330B1 (en) | 1986-02-25 | 1987-02-24 | SEPARATING AGENT FOR CONSTITUENTS OF A LIQUID AND METHOD USING SUCH AN AGENT |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61039736A JPH06100595B2 (en) | 1986-02-25 | 1986-02-25 | Liquid separating agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62197765A JPS62197765A (en) | 1987-09-01 |
| JPH06100595B2 true JPH06100595B2 (en) | 1994-12-12 |
Family
ID=12561249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61039736A Expired - Fee Related JPH06100595B2 (en) | 1986-02-25 | 1986-02-25 | Liquid separating agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH06100595B2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0734011B2 (en) * | 1986-02-27 | 1995-04-12 | 三菱化学株式会社 | Liquid separating agent |
| CA2004535A1 (en) * | 1988-12-08 | 1990-06-08 | Toru Tagawa | Liquid separating agent |
| JPH02168159A (en) * | 1988-12-22 | 1990-06-28 | Mitsubishi Kasei Corp | blood separation agent |
| JPH04203965A (en) * | 1990-11-29 | 1992-07-24 | Sekisui Chem Co Ltd | Composition for separating serum or plasma |
| KR100579489B1 (en) | 2003-12-11 | 2006-05-12 | 이진우 | Biomaterial measuring device and manufacturing method |
| AT528233A1 (en) * | 2024-04-29 | 2025-11-15 | Greiner Bio One Gmbh | Separating gel for blood collection tubes |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5837560A (en) * | 1981-08-31 | 1983-03-04 | Nippon Paint Co Ltd | Sealant for separation of serum or plasma |
| US4751001A (en) * | 1984-09-24 | 1988-06-14 | Becton Dickinson And Company | Blood partitioning apparatus |
-
1986
- 1986-02-25 JP JP61039736A patent/JPH06100595B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPS62197765A (en) | 1987-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0035575B1 (en) | Blood serum-separating agent | |
| EP0039898A1 (en) | Apparatus for separating blood | |
| JP3063799B2 (en) | Blood separation agent | |
| US4350593A (en) | Assembly, compositions and method for separating blood | |
| US4534798A (en) | Composition for partitioning blood components | |
| US3876376A (en) | Linear determination of hemolytic complement activity in undiluted serum | |
| GB2029848A (en) | Thixotropic gel like compositons and sterile blood collecting and separating device | |
| SE431821B (en) | STORAGE STABLE, PROSTAGLANDIN-CONTAINING MEDICAL PREPARATION | |
| CN104634957A (en) | Composition for separation of serum or plasma and container for blood test | |
| JPH035550B2 (en) | ||
| JPH06100595B2 (en) | Liquid separating agent | |
| Hildgen et al. | A new gradient matrix: formulation and characterization | |
| CZ193392A3 (en) | Agent for blood separation | |
| US4387031A (en) | Compositions able to separate the erythrocytes from the serum or plasma in blood analysis samples, and the method which uses them | |
| EP0520184B1 (en) | Blood separation means | |
| US5814220A (en) | Process for producing blood separating agent | |
| GB2132759A (en) | Blood collecting tube | |
| JPH0734011B2 (en) | Liquid separating agent | |
| JPH1164330A (en) | Gel blood separation material and blood separator | |
| Marriott et al. | The release of antibacterial agents from glycerolgelatin gels | |
| JPH10282092A (en) | Method of maintaining serum or plasma separating agent form | |
| GLANTZ et al. | Surface and colloid chemical aspects of saliva particle interactions | |
| JPS5837560A (en) | Sealant for separation of serum or plasma | |
| JP2002365282A (en) | Composition for serum or plasma separation | |
| Bergren et al. | Investigation of the relationship between melting-related parameters and in vitro drug release from vaginal suppositories |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |